Document Detail


Effects of Prolastin C (Plasma-Derived Alpha-1 Antitrypsin) on the Acute Inflammatory Response in Patients With ST-Segment Elevation Myocardial Infarction (from the VCU-Alpha 1-RT Pilot Study).
MedLine Citation:
PMID:  25456867     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Alpha-1 antitrypsin (AAT) has broad anti-inflammatory and immunomodulating properties in addition to inhibiting serine proteases. Administration of human plasma-derived AAT is protective in models of acute myocardial infarction in mice. The objective of this study was to determine the safety and tolerability of human plasma-derived AAT and its effects on the acute inflammatory response in non-AAT deficient patients with ST-segment elevation myocardial infarction (STEMI). Ten patients with acute STEMI were enrolled in an open-label, single-arm treatment study of AAT at 60 mg/kg infused intravenously within 12 hours of admission and following standard of care treatment. C-reactive protein (CRP) and plasma AAT levels were determined at admission, 72 hours, and 14 days, and patients were followed clinically for 12 weeks for the occurrence of new onset heart failure, recurrent myocardial infarction, or death. Twenty patients with STEMI enrolled in previous randomized trials with identical inclusion and/or exclusion criteria, but who received placebo, served as historical controls. Prolastin C was well tolerated and there were no in-hospital adverse events. Compared with historical controls, the area under the curve of CRP levels was significantly lower 14 days after admission in the Prolastin C group (75.9 [31.4 to 147.8] vs 205.6 [78.8 to 410.9] mg/l, p = 0.048), primarily due to a significant blunting of the increase occurring between admission and 72 hours (delta CRP +1.7 [0.2 to 9.4] vs +21.1 [3.1 to 38.0] mg/l, p = 0.007). Plasma AAT levels increased from admission (149 [116 to 189]) to 203 ([185 to 225] mg/dl) to 72 hours (p = 0.005). In conclusion, a single administration of Prolastin C in patients with STEMI is well tolerated and is associated with a blunted acute inflammatory response.
Authors:
Antonio Abbate; Benjamin Wallace Van Tassell; Sanah Christopher; Nayef Antar Abouzaki; Chiara Sonnino; Claudia Oddi; Salvatore Carbone; Ryan David Melchior; Michael Lucas Gambill; Charlotte Susan Roberts; Michael Christopher Kontos; Mary Ann Peberdy; Stefano Toldo; George Wayne Vetrovec; Giuseppe Biondi-Zoccai; Charles Anthony Dinarello
Related Documents :
24433707 - Diagnostic accuracy of stress perfusion cmr in comparison with quantitative coronary an...
24450057 - Electrocardiograms of bottlenose dolphins (tursiops truncatus) out of water: habituated...
9227307 - Coronary involvement in the churg-strauss syndrome.
23765847 - Use of regadenoson for measurement of fractional flow reserve.
21499497 - Cardiac mass in a patient with colorectal cancer: "not all that glitters is gold!".
8407727 - An autopsy case of intracranial hemorrhage during tissue plasminogen activator infusion.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-10-13
Journal Detail:
Title:  The American journal of cardiology     Volume:  -     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2014 Oct 
Date Detail:
Created Date:  2014-12-2     Completed Date:  -     Revised Date:  2014-12-3    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2014 Elsevier Inc. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcomes of Patients Calling Emergency Medical Services for Suspected Acute Cardiovascular Disease.
Next Document:  Relation of Physical Activity to Prevalence of Nonalcoholic Fatty Liver Disease Independent of Cardi...